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Available online xxxxBackground: Knowledge of the natural history of colorectal adenomas is limited because these lesions are
removed upon detection. The few studies in which small adenomas have been left in situ for a limited period
of time, have shown that most lesions remain stable or even completely regress. Speciﬁc DNA copy number
changes (‘cancer associated events’ or CAEs) are associated with progression of adenomas to cancer. In this
study we evaluated whether molecular features of progression correlated with growth of small polyps.
Methods: Small (6–9 mm) colorectal precursor lesions detected on CT-colonography (CTC) were left in situ and
re-evaluatedwith CTC after three years. Based on volumetric change, polyps were classiﬁed as either grown, sta-
ble or regressed. Surveillance CTC was followed by colonoscopy, during which all lesions were resected. Using
DNA isolated from FFPE polyp tissues, low-coverage whole genome sequencing was performed to determine
DNA copy number proﬁles, as well as target enrichment mutation analysis and CpG island methylation pheno-
type (CIMP) analysis. Expression of DNA mismatch repair (MMR) proteins was determined by immunohisto-
chemistry. Samples were marked as MMR proﬁcient if all MMR proteins were expressed.
Findings: Out of 68 polyps resected at colonoscopy, for 65 (96%) material was available. Of these, 31 (48%) had
grown, 27 (41%) remained stable and 7 (11%) regressed. Polyps with at least one CAE had higher growth rates
compared to polyps without CAEs (difference 91% growth (95% CI 13–169), p = .023). CAEs were absent in
lesions that had partially regressed. Mutations occurred in 94% of the polyps, with higher growth rates being
associated with polyps having ≥2 mutations compared to lesions with only 0–1 mutations (difference 99%
growth (95% CI 9–189), p = .032). All samples were MMR proﬁcient. No relation between growth and CIMP
was observed.
Interpretation:Molecular alterations associated with colorectal cancer, correlated with growth of small polyps
and were absent in polyps that regressed. Therefore, this longitudinal study provides in vivo support in the
human setting for the functional role of thesemolecular alterations, that havemostly been identiﬁedby cross sec-
tional observations in tissue samples of colorectal adenomas and cancers.
Fund: Alpe d'Huzes- Dutch Cancer Society (project number NKI2013-6338).
© 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Molecular proﬁling1. Introduction
The development of colorectal cancer (CRC) is a stepwise process, in
which normal epithelial cells transform into an adenocarcinoma
through a benign intermediate lesion (i.e. mostly adenomas, but alsoen access article under the CC BY-NC
, B. Carvalho, C. Rausch, et al.,
/10.1016/j.ebiom.2018.12.00serrated polyps). While the prevalence of adenomas is high, only a
minority of approximately 5% eventually progresses into cancer; the re-
maining lesions do not convert tomalignancy or even completely disap-
pear over time [1,2]. Understanding the natural history of disease is at
the basis of all strategies for early detection of cancer. In the case of co-
lorectal adenoma to carcinoma progression, the absence of longitudinal
observations, like we do have in for instance Barrett's oesophagus and
cervical cancer [3], causes an evident blind spot in our knowledge of
this disease. Molecular analysis of colorectal polyps that have been left-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Research in context
Evidence before this study
We searched Pubmed (from June 1, 2015 up to March 1, 2018)
with a combination of relevant key terms including: colonic le-
sions, polyps, natural history, evolution, growth, progression,
follow-up, mutation, copy number changes and molecular profile.
Inherent to the fact that colorectal polyps are removed once de-
tected on endoscopy, molecular features of these lesions cannot
be correlated to longitudinal observations on phenotype changes.
Therefore, the knowledge on the biology of colorectal cancer pro-
gression gathered up to now is mainly based on cross-sectional
studies. Next to the sequence of mutations classically associated
with adenoma to carcinoma progression, we have previously
shown that certain DNA copy number alterations are associated
with progression of cancer. In one study where polyps were left
in situ and followed up in time, mutation burden was correlated
with polyp growth. However, comprehensive analysis of DNA al-
terations (i.e. sequence mutations, promoter methylation, DNA
copy number changes andMMR status) in longitudinally observed
polyps has never been performed. To enhance our understanding
of the natural course of disease in colorectal polyps, we set out
to assess the association between DNA alterations and in vivo
growth in small colorectal polyps.
Added value of this study
We had access to a unique set of 65 small polyps that had been
followed longitudinally, and performed a comprehensive analysis
of DNA alterations in these polyps, including DNA copy number,
mutation, CIMP and MMR status. For the first time we were able
to show that regressed polyps did not harbour DNA copy number
alterations or mutations associated with later stages of polyp to
cancer progression. Higher growth rates were observed in lesions
with cancer associated DNA copy number alterations (cancer as-
sociated events or CAEs), aswell as in lesions with a higher muta-
tion burden.
Implications of all the available evidence
Since approximately only 5% of all colorectal adenomas eventu-
ally progress to cancer, strategies for early detection ideally should
focus on identifying only those 5%of lesions that progress and ig-
nore the 95% of polyps that will not harm patients. In this in vivo
human longitudinal studywehave provided insights in theDNA al-
terations of small colorectal polyps and their growth over time.
These insights can guide the development of new specific and
sensitive screening and surveillance methods.
2 M.C.J. van Lanschot et al. / EBioMedicine xxx (2018) xxxin situ for a few years, even if this concerns small lesions only, provides a
unique opportunity to ﬁll some of these gaps.
Cross-sectional studies have shown that adenomas larger than
10 mm have a higher risk of harbouring a focus of cancer (2.1–6.9%),
compared to small 6–9 mm lesions (0–0.42%) [4]. During adenoma for-
mation and subsequent malignant progression, several cell signalling
pathways get disrupted. An early event is the disruption of theWNT sig-
nalling pathway by mutation of the APC gene, followed bymutations in
the RAS-MAPK, PI3K-AKT, TGF-ß, and p53 pathways in later stages of
progression [5]. The increased rate of new mutations is facilitated by
the acquisition of some form of genomic instability, most commonly
chromosomal instability (CIN) that is present in about 85% of sporadic
CRCs [6]. DNA copy number alterations particularly associated withPlease cite this article as: M.C.J. van Lanschot, B. Carvalho, C. Rausch, et al.,
A cohort study, EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.12.00the transition from adenoma to carcinoma are gains in 8q, 13q and
20q and losses in 8p, 15q, 17p and 18q [7–9]. The presence of two or
more of any of these seven CAEs marked adenomas at high risk of pro-
gression with high accuracy (78% sensitivity and 78% speciﬁcity) [7].
Besides adenomas, also serrated polyps have been recognised as pre-
cursors lesions. In serrated polyps a BRAFmutation is typically the initi-
ating event, leading to increased gene promoter hypermethylation
(CpG island methylation phenotype or CIMP). When hypermethylation
affects the expression of the mismatch repair (MMR) genes, this gives
rise to another form of genomic instability, known as microsatellite in-
stability (MSI) [10].
Although the molecular events occurring during CRC development
have been widely studied, most observations are from cross-sectional
studies as precursor lesions are removed upon detection at colonoscopy.
In a few CT-colonography (CTC) studies in which small polyps were left
in situ, adenoma growth during follow-up was associated with an ad-
vanced adenoma phenotype at resection [2,11]. The aim of the present
studywas to assesswhether polyp growthwas related tomolecular fea-
tures of colorectal cancer. For this purpose, we used a unique series of
patients with small (6–9 mm) colorectal lesions initially identiﬁed by
CTC, that were left in situ and ultimately resected after a surveillance in-
terval of three years. This allowed longitudinal assessment of lesion size
(i.e. growth) in relation to histological and molecular characteristics at
time of resection.
2. Methods
2.1. Study design and participants
In a Dutch multi-centre, randomised controlled screening trial (CO-
lonoscopy or COlonography for Screening (COCOS) trial, 2009–2010,
trial number: 2009/03WBO and NTR1829, The Hague, Netherlands)
comparing primary colonoscopy to CTC [12], patients in the CTC-arm
with one or two small 6–9 mm colorectal lesions were advised to un-
dergo a surveillance CTC after an interval of three years. Patients with
more than two 6–9mmpolyps or larger polyps on baselineCTCwere re-
ferred for colonoscopy directly and therefore not included in thepresent
follow-up study. The 95 small lesions detected on index CTC in this pa-
tient subpopulation were thus left in situ and re-measured at follow-up
to assess the percentage of volumetric change for each lesion over the
entire surveillance interval [2]. Based on volumetric change on CTC
over the entire surveillance interval as proportion of baseline volume,
lesions were classiﬁed as either grown (N30% growth), stable (b30% re-
gression to b30% growth) or regressed (N30% regression). Details of this
method and the choice of the 30% cut-off are described elsewhere [2].
Following the surveillance CTC, all patients were offered a colonoscopy
for resection of the lesions. Location and size of the polyp on colonos-
copy were recorded. The distal colon was deﬁned as rectum and sig-
moid. From those lesions for which histopathology was available,
formalin ﬁxed parafﬁn-embedded (FFPE) material was retrieved and
reviewed by an expert pathologist (GAM). Based on histopathology
and size at colonoscopy, lesions were classiﬁed as non-advanced ade-
noma, advanced adenoma, non-advanced serrated polyp or advanced
serrated polyp according to the deﬁnitions summarised in Table 1.
Ethics approval from the Dutch Health Council was obtained for
COCOS, including surveillance CTC after 3 years. Patients had already
given their written informed consent to be contacted for follow-up
studies and consented to this study.
2.2. Procedures
2.2.1. DNA isolation
DNA was isolated as previously described [13]. In brief, DNA from
FFPE material was isolated following micro-dissection (N 70% tumour
cells). A six-day incubation period with proteinase K in lysis buffer
(ATL buffer, QIAmp, DNA micro-kit, Qiagen, Venlo, The Netherlands)Molecular proﬁling of longitudinally observed small colorectal polyps:
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Table 1
Classiﬁcation of colorectal polyps.
Lesion type Abbreviation Deﬁnition
Non-advanced
adenoma
NAA tubular adenoma (TA) b10 mm with low-grade
dysplasia
Advanced
adenoma
AA adenoma ≥10 mm and/or with high-grade
dysplasia and/or a villous component of ≥25%
Non-advanced
serrated polyps
NASP hyperplastic polyp (HP), sessile serrated lesion
(SSL), or traditional serrated lesion (TSL) b10
mm without dysplasia
Advanced
serrated polyp
ASP hyperplastic polyp (HP), sessile serrated lesion
(SSL), or traditional serrated lesion (TSL) ≥10
mm and/or with dysplasia
3M.C.J. van Lanschot et al. / EBioMedicine xxx (2018) xxxwas performed. Every day, proteinase K (10 μl or 20 ng/μl) was freshly
added. DNA was isolated using the QIAmp DNA micro-kit (Qiagen)
and concentrations and purity were measured on a Nanodrop ND-
1000 spectrophotometer (Isogen, IJsselstein, The Netherlands). Isolated
DNAwas used as input for copy number analysis, mutation analysis and
CIMP analysis, in that order speciﬁcally.
2.2.2. DNA copy number analysis
DNA copy number changeswere analysedwith low-coveragewhole
genome sequencing (WGS) [14]. Brieﬂy, DNA was fragmented by soni-
cation (Covaris S2, Woburn, MA, USA) and run on the HiSeq 2500
(Illumina, San Diego, CA, USA) on a 65 basepairs single-read modus
using the KAPA HyperPrepKit (KAPA Biosystems, KK8504, Wilmington,
MA, USA). This yielded a coverage of 0.13× (IQR 0.12–0.14) genome
coverage. The WGS reads were analysed with Bioconductor R-package
QDNAseq, using a publishedworkﬂow [15]. For every ﬁxed-sized region
of 30 kb on the genome, the relative abundance of sequence reads was
used to determine the aberration status, applying corrections for
mappability and GC content and removing germ-line speciﬁc variations
[14]. Awavy pattern seen in copy number plots, ‘genomicwaves’, which
may be caused by replication timing of proliferating cells [16], were
smoothed usingNoWaves [17]. This algorithmuses a set of normal sam-
ples (in this case of patients with CRC) [18] as reference to correct bins
(genomic intervals) which systematically obtain a higher or lower sig-
nal. The obtained copy number proﬁles were segmented into regions
of constant log2-read count and aberrations were called as high-level
ampliﬁcation [2], gain [1], normal (0), loss (−1) or homozygous dele-
tion (−2). When the number of called copy number segments was
above 200 over the whole genome, while at the same time had a very
a high difference between expected and observed noise (N1.5 times
the interquartile range of values of all analysed samples), samples
were excluded for further analysis. When ≥2 CAEs were present, the le-
sion was marked as a high-risk adenoma.
2.2.3. Mutation analysis
Samples inwhichDNAwas still available after copynumber analysis,
were subjected tomutation analysis. DNA libraries were prepared using
the KAPA HyperPrep Kit (KAPA Biosystems, Wilmington, MA, USA) as
described in the KAPA HyperPrep Kit protocol (KR0961 – v5.16). Target
enrichmentwas performed using a custom48 gene xGen® Predesigned
Gene Capture Pools (Integrated DNA Technologies, San Diego, CA, USA),
according to the Rapid Protocol for DNA Probe Hybridisation and Target
Capture Using an Illumina TruSeq® Library, Version 2.1, with an ex-
tended hybridisation reaction of 24 h. The gene panel consisted of 48
cancer-related genes, including genes most often mutated in colorectal
cancer such asAPC, KRAS,NRAS, PIK3CA, SMAD4, TP53 and BRAF (Supple-
mentary table 1). Paired-end 65 bp sequencing data were generated
with Illumina Hiseq 2500 (Illumina, San Diego, CA, USA), yielding a me-
dian of 89× (IQR 55–148) coverage in the target regions, after removal
of duplicate reads. The target regions, spanning the exonic sequences
of the 48 genes, covered ~3.55 × 105 bp in total.Please cite this article as: M.C.J. van Lanschot, B. Carvalho, C. Rausch, et al.,
A cohort study, EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.12.00After adapter trimming, the reads were aligned to the human refer-
ence GRCh38 with BWA-MEM [19]. Subsequently base quality scores
were recalibrated and the variants were called according to the GATK
HaplotypeCaller [20]. Variant effects prediction was performed using
SnpEff [21] and external data sources were linked using SnpSift [22].
To excludeDNApolymorphisms present in the normal populations, var-
iants reported in dbSNP as ‘common’ or ‘G5’ were excluded. Further-
more, variants present at ≥1% in the ExAC exome data [23] and
variants affecting non-coding sequences were excluded. Variants were
required to have a ‘medium’ or ‘high’ effect, according to SnpEff,
which led to the exclusion of silentmutations. Mutationswere summed
per gene and per sample using a representation called Oncoprint, which
was created using R Bioconductor, package ComplexHeatmap.2.2.4. CIMP analysis
Samples inwhichDNAwas still available after copynumber andmu-
tation analyses, underwent sodium bisulﬁte modiﬁcation (EZ DNA
methylation kit, ZYMO research Co., Orange, CA, USA) to determine
CIMP status. Nested methylation speciﬁc PCR (nested-MSP) for the
CIMP marker panel as deﬁned by Weisenberger [24] was performed
as described earlier [25]. Ten μl of each MSP reaction was loaded onto
a 2% agarose gel, stained with GelStar and visualised using ultraviolet
light. Polyps were deﬁned as CIMP-high when ≥3 of the 5 markers
(CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1) from the CIMPmarker
panel were methylated.2.2.5. MMR-status analysis
Immunohistochemistry (IHC) of the FFPE tumour samples was per-
formed on a BenchMark Ultra autostainer (Ventana Medical Systems,
Oro Valley, AZ, USA). Brieﬂy, parafﬁn sections were cut at 3 μm, heated
at 75 °C for 28 min and deparafﬁnised with EZ prep solution. Heat-
induced antigen retrieval was carried out using Cell Conditioning 1 for
32 min at 95 °C (MSH2, MSH6 and PMS2), or 64 min at 95 °C (MLH1).
MLH1 was detected using clone M1 (Ready-to-Use, 32 min at 37 °C,
Ventana Medical systems), MSH2 using clone G219–1129 (Ready-to-
Use, 12 min at 37 °C, Ventana Medical systems), MSH6 using clone
EP49 (1/50 dilution, 32 min at 37 °C, Epitomics, Burlingame, CA, USA)
and PMS2 using clone EP51 (1/40 dilution, 32 min at 37 °C, Dako).
For PMS2 signal ampliﬁcation was applied using the Optiview Am-
pliﬁcation Kit (4 min, Ventana Medical Systems). Bound antibody was
detected using theOptiViewDABDetection Kit and slideswere counter-
stained with Hematoxylin and Bluing Reagent (Ventana Medical Sys-
tems, Oro Valley, AZ, USA).
The slides were scored for positivity by an expert pathologist (GAM
or PS). In case of positivity of the four MMR genes, the sample was con-
sidered MMR proﬁcient. In case expression of one or more MMR genes
was lost, the sample was considered MMR deﬁcient.2.3. Statistics analysis
Supported by the observation that colorectal polyps originating from
the same patient differed in morphology, colonic location, histopathol-
ogy and/or growth, all colorectal lesionswere assumed to develop inde-
pendently (Supplementary table 2). For comparisons of numerical
data between two unpaired subgroups, the independent t-test was
used. For comparison of categorical data between unpaired subgroups
the Chi-square test or Fischer's Exact test was used. For all test, two-
sided p ≤ .05 was considered signiﬁcant. For the comparison of aberra-
tion frequencies between two groups, R-package CGHtest was applied,
which runs a Chi-square test and a Wilcoxon rank-sum test. A multiple
testing correction to the p-values was performed according to the
Benjamini and Yekutieli FDR rule, using a cut-off for signiﬁcance of
0.10 [26].Molecular proﬁling of longitudinally observed small colorectal polyps:
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Table 2
Clinicopathological characteristics of the 65 longitudinally observed polyps per growth
category.
Grown Stable Regressed
All polyps (n= 65) n= 31 n= 27 n= 7
Location
Proximal 16 (52%) 11 (41%) 5 (71%)
Distal 15 (48%) 16 (59%) 2 (29%)
Morphology
Sessile 16 (52%) 14 (52%) 6 (86%)
Pedunculated 9 (29%) 11 (41%) 1 (14%)
Flat 6 (19%) 2 (7%) 0
Adenomas (n= 56) n= 27 n= 23 n= 6
Histology
Tubular 20 (74%) 21 (91%) 6 (100%)
Tubullovillous 7 (26%) 2 (9%) 0
Villous 0 0 0
Dysplasia
Low-grade 27 (100%) 23 (100%) 6 (100%)
High-grade 0 0 0
Serrated polyps (n= 9) n= 4 n= 4 n= 1
Histology
Sessile serrated 1 (25%) 0 0
Hyperplastic 3 (75%) 4 (100%) 1 (100%)
Dysplasia
Absent 4 (100%) 4 (100%) 1 (100%)
Present 0 0 0
4 M.C.J. van Lanschot et al. / EBioMedicine xxx (2018) xxx2.4. Data depository
Sequence data has been deposited at the European Genome-
phenome Archive (EGA), which is hosted by the EBI and the CRG,
under accession number EGAS00001003284 [27].
3. Results
3.1. Histopathology
Of the 68 polyps resected at the surveillance colonoscopy, material
was available for 65 (96%) polyps (Fig. 1). These 65 polyps came from
46 patients (57% male, mean age 66.7 (s.d. 6∙9) years) who had a
mean surveillance interval of 3.3 (s.d. 0.29) years. The lesions included
47 (72%) tubular adenomas (TAs) with low grade dysplasia (LGD), 9
(14%) tubulovillous adenomas (TVAs) with LGD, 1 (2%) sessile serrated
lesion (SSL) without dysplasia and 8 (12%) hyperplastic polyps (HPs)
without dysplasia (Table 2). When using the 30% threshold of volumet-
ric change [2], 48% (31/65) of the lesions had grown, 41% (27/65)
remained stable and 11% (7/65) regressed (Table 2).
Histopathological features and molecular proﬁles of the 65 polyps,
ranked by growth rate, are summarised in Fig. 2. Of the adenomas,
36% (20/56) were classiﬁed as advanced adenomas (Table 1 and
Fig. 2B). All nine serrated polyps were classiﬁed as non-advanced ser-
rated polyps.
In relation to histopathology, growth rates were signiﬁcantly higher
in TVAs compared to TAs (difference 121% growth (95% CI 42–200), in-
dependent t-test, p=.003, Fig. 3A). Also growth rateswere signiﬁcantly
higher in polyps that were advanced adenomas at resection compared
to non-advanced adenomas (difference 80% growth (95% CI 18–142),
independent t-test, p= .012, Fig. 3B).
3.2. DNA copy number analysis
Good quality DNA was obtained from 59 of the 65 retrieved lesions.
The copy number proﬁles of 4/59 samples did not meet the quality
criteria, leaving 55 lesions for analysis (Fig. 4). These concerned 48 ade-
nomas and seven serrated polyps (6 HPs and 1 SSL). Twenty percent95 Polyps on index CT-colonograp
82 Polyps red
14 Polyps without histopathologyⱡ
13 Polyps resolved*
Fig. 1. Flow-chart of polyps followed longitudinally after initial CT-colonography (CTC) detectio
quality of fecal tagging in the relevant segments for 12 out of the 13 polyps. ⱡ14 polyps had no
polyp at surveillance CTC) (n = 5), the patient refused colonoscopy (n = 5) or polyps were n
Please cite this article as: M.C.J. van Lanschot, B. Carvalho, C. Rausch, et al.,
A cohort study, EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.12.00(11/48) of adenomas, but none of the serrated polyps showed at least
one CAE (Fig. 2B). In these adenomas, 13q gain was the most common
CAE (91%, 10/11), followed by 20q gain (4/11: 36%), 8q gain (3/11;
27%) and 17p loss (9%; 1/11) (Supplementary table 3).
The mean growth rate of lesions with CAEs was signiﬁcantly higher
in lesions with ≥1 CAEs, compared to lesions without CAEs (difference
91% growth (95% CI 13–169), independent t-test, p = .023, Fig. 5A).
CAEs were absent in the ﬁve lesions that had regressed. Based on the
molecular deﬁnition of having ≥2 CAEs, 10% (5/48) of the adenomas
were classiﬁed as being at high risk for progression. Two of these
high-risk adenomas were advanced adenomas that had grown, onehy
etected on surveillance CT-colonography
68 Polyps with histopathology
2 FFPE blocks missing
66 Polyps with FFPE blocks retrieved
1 no tissue left in FFPE 
block
65 Polyps available for evaluation
n. *13 polyps could not be redetected at surveillance CTC, despite good distention and good
histopathological diagnosis, because the patient was not referred for colonoscopy (b6 mm
either detected (n= 3), nor retrieved (n= 1) during colonoscopy.
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Fig. 2.Molecular proﬁle and histopathological features ordered by growth rate for hyperplastic polyps and sessile serrated lesions (left), tubulovillous adenomas (middle) and tubular
adenomas (right). Each vertical column represents an individual lesion. A. Mutational proﬁle. Only genes that have a mutation in at least one of the samples are shown. The top bars
represent the number of mutations per sample. Percentages on the left indicate the prevalence of a speciﬁc mutation over all the analysed samples. B. Histopathological features and
molecular proﬁle resulting from copy number analysis, CIMP analysis and immunohistochemistry of the mismatch-repair genes. Several samples could not undergo the entire range of
molecular analyses due to limited DNA available. Histology: TA = tubular adenoma, TVA = tubulovillous adenoma, HP = hyperplastic polyp, SSL = sessile serrated lesion; Lesion
type: NASP = non-advanced serrated polyp, NAA = non-advanced adenoma, AA = advanced adenoma; CAE = cancer associated event, which includes chromosomal gains in 8q, 13q
and 20q and losses in 8p, 15q, 17p and 18q. The presence of ≥2 CAEs deﬁnes high-risk adenomas. Four samples were excluded from DNA copy number analysis due to poor quality;
CIMP = CpG island methylation phenotype; MMR =mismatch repair. C. Growth rates according to CT-colonography measurement during the 3-year surveillance interval. Patient ID
is depicted in colour marking only for patients with N1 polyp.
5M.C.J. van Lanschot et al. / EBioMedicine xxx (2018) xxxwas an advanced adenoma that had remained stable, one was a non-
advanced adenoma that had remained stable and one was a non-
advanced adenoma that had grown (Fig. 2B).
3.3. Mutation analysis
Mutation analysis could be successfully completed for 34 samples
(Fig. 4), including 31 adenomas and three serrated polyps (2 HPs and
1 SSL). One or more mutations were observed in 94% (32/34) of the
samples (median 2, range 0–5). Mutations of the WNT pathway were
found in 74% (23/31) of adenomas, including APC mutation as the
most common overall alteration in 61% (19/31) and CTNNB1mutation
in 16% (5/31) (Fig. 2A). Only one adenoma had a mutation in both the
APC and CTNNB1 genes; in all other samples these mutations were mu-
tually exclusive. The PI3K-AKT pathway was affected in one adenoma
(3%) with a mutation in the PTEN gene. Genetic alterations in the RAS-
MAPK pathway occurred in 10% (3/31) of the adenomas, concerningPlease cite this article as: M.C.J. van Lanschot, B. Carvalho, C. Rausch, et al.,
A cohort study, EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.12.00two KRASmutations (6%; 2/31) and one mutation in ERBB2. No muta-
tionswere found in the TGFβ pathway. Sixteen percent (5/31) of adeno-
mas showed mutations in the p53 pathway 16% (5/31), occurring in
ATM (16%; 5/31) and/or TP53 (3%; 1/31). In the serrated polyps, BRAF
was the only mutation detected (67%; 2/3).
Mutation burden correlated with growth: those lesionswith ≥2mu-
tations had higher growth rates compared to lesions with only 0–1mu-
tations (difference 99% growth (95% CI 9–189), independent t-test, p=
.032, Fig. 5B). APCmutations were present in all growth categories. Six
of the 19 (32%) samples with APC mutations also carried one or more
mutations in the PI3K, RAS-MAPK, or p53 pathways. Such combinations
were not found in lesions that had regressed.
3.4. CIMP analysis
CIMP status was determined on all 27 samples in which DNA was
still available (Fig. 4). These were 25 adenomas and two serrated polypsMolecular proﬁling of longitudinally observed small colorectal polyps:
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(Fig. 2B). Both of the serrated polyps were CIMP positive and located
in the distal colon. In the small number of polyps on which CIMP analy-
sis was performed, no statistically signiﬁcant difference could be
observed.
3.5. MMR-status analysis
In all 58 samples (51 adenomas and 7 serrated polyps) that were
assessed by IHC (Fig. 4), expression of MLH1, MSH2, MSH6 and PMS2Histopathological 
56 adenomas and 9
MOLECULAR
Excluded (n=7)
Insufficient tissue
Immunohistochemistry
MMR analysis (n=58)
51 adenomas and 7 serrated polyps
Fig. 4. Flow-chart of polyp samples used for molecular analyses. CIMP
Please cite this article as: M.C.J. van Lanschot, B. Carvalho, C. Rausch, et al.,
A cohort study, EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.12.00proteins was present (Supplementary ﬁg. 1), hence these were all clas-
siﬁed as MMR proﬁcient (Fig. 2B).4. Discussion
In the present study, we sought to evaluate whether growing colo-
rectal polyps showed distinct molecular features associated with pro-
gression, compared to lesions that regressed or remained stable over
time. To this aim, we performed detailed molecular analyses in a set ofrevision (n=65) 
 serrated polyps
 ANALYSIS
Copy number analysis (n=55)
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after initial identiﬁcation by CTC.
Higher growth rates were related to presence of non-random DNA
copy number alterations associated with colorectal adenoma to carci-
noma progression (cancer associated events or CAEs), as well as to in-
creased mutation burden. Regressed lesions did not show CAEs, but
did have mutations in genes involved in common CRC pathways,
which concerned mostly APC mutations. Because APC inactivation is
such an early event in adenoma genesis, it may not prevent lesions
from regressing. The only mutation besides APC that was present in
one of the regressed lesionswas in the SMO gene, a raremutation occur-
ring in 0.9% of CRCs [28]. The SMO protein is a component of the hedge-
hog signalling pathway, which has been shown to negatively regulate
WNT signalling [29]. In gastric cancers, however, SMOmutations were
found not to be associated with altered expression of hedgehog target
genes, indicating that these are probably passenger mutations [30].
Our observation that multiple mutations are already present in a
substantial proportion of small colorectal polyps is in linewith previous
observations that detectable mutations occurred at an early stage of
polyp development, at a mean size of only 30 ± 35 crypts [31,32]. For
perspective; lesions of 10mm3 contain approximately 3 × 105 crypts.
Many of the somaticmutations detected in tumoursmay occur even be-
fore morphologically recognisable tumour formation [33,34]. Recent
data show that in ~1% of morphologically normal colorectal crypts
driver mutations were already present [35]. In approximately one
third of the adenomas (6/19; 32%) with APCmutations, also mutations
in the PI3K, RAS-MAPK, or p53 pathways occurred. However, only two
of these adenomas with additional mutations in the PI3K, RAS-MAPK,
or p53 pathways were at high risk of progression based on the criterion
of having ≥2 CAEs [7]. Accumulating evidence suggests that whereas
mutations in driver genes are already present early in precancerous le-
sions, chromosomal instability is a late phenomenonduring adenoma to
carcinoma progression [36]. Therefore, copy number alterations likely
play amore critical role inmalignant transformation. This is functionally
supported by the observation that engineered patient-derived, ade-
nomaorganoidswith critical drivermutations, only obtainedmetastatic
capacity when CINwas present [37]. The results from our study conﬁrm
that mutations, present in regressed, stable and grown lesions, do not
reﬂect polyp risk of progression, whereas CAEs, only present in stable
and grown lesions, may likely do so.
Identifying adenomas with a high progression risk is of value for
clinical practice. At the current moment, adenomas ≥10 mm, with vil-
lous component or high-grade dysplasia are considered high risk - or
advanced - adenomas. Yet, this deﬁnition gives a suboptimal estimation
of the true risk of progression and has been introduced and adopted inPlease cite this article as: M.C.J. van Lanschot, B. Carvalho, C. Rausch, et al.,
A cohort study, EBioMedicine, https://doi.org/10.1016/j.ebiom.2018.12.00literature without much evidence [38]. The presence of more ≥2 CAEs
more precisely reﬂects the natural course of the disease and more spe-
ciﬁcally identiﬁes adenomas at high risk of progressing to cancer [7].
Previous research has shown that only 25% of advanced adenomas
and 3% of non-advanced adenomas presented with ≥2 CAEs [39], sug-
gesting that the majority of advanced adenomas should not be consid-
ered high risk, whereas a small proportion of non-advanced adenomas
should. The problem associated with the deﬁnition of advanced ade-
noma, is also reﬂected by studies that investigated the relationship be-
tween polyp growth and the risk of progression, taking advanced
adenomas as the endpoint [2,11]. In the original description of our co-
hort [2], the rates of advanced adenomas were 47%, 21% and zero in
progressed, stable and regressed lesions, respectively. As 6–9 mm
polyps that grow will easily qualify as advanced adenoma, when
reaching 10 mm or more, we hypothesised that these rates were an
overestimation of the actual risk of progression. Indeed, when focusing
on molecular features rather than phenotypical features to deﬁne high-
risk adenomas, only 13% of the adenomas that had grown, 11% of the
stable adenomas and none of the regressed adenomas had ≥2 CAEs. Al-
though numbers are small, these last rates appear to bemore consistent
with the actual progression risk, as it is estimated that approximately 5%
of adenomas eventually progress to cancer [1].
The application of CAEs to identify high risk adenomas could be used
in the development of novel diagnostic screening tests. After all, screen-
ing programs ideally should aim to detect precursor lesions just before
they transform to colorectal cancer, in order to reduce both cancer inci-
dence and mortality. In addition, molecularly-deﬁned high risk adeno-
mas could impact surveillance. According to the current post-
polypectomy colonoscopy surveillance guideline, the presence of ad-
vanced adenomas shortens the surveillance interval [40]. In our study
a total of 18 patients had at least one advanced adenoma based on phe-
notypical features at follow-up colonoscopy, compared to ﬁve patients
based on molecular features (of which only three overlapping between
the groups), which suggests overdiagnosis is happening with the cur-
rent strategy. With the technical advancements over the recent years
low cost and fastmethods for copy number proﬁlinghave become avail-
able [41]. This makes the use of CAEs for risk stratiﬁed surveillance a re-
alistic approach, although ﬁrst further research is needed to assess the
correlation between the presence of molecularly-deﬁned high risk ade-
nomas and the risk of metachronous lesions.
The use of CAEs as progression biomarker only applies to adenomas
and not to serrated polyps. In the present cohort, CAEs were absent in
serrated polyps irrespective of their growth category. This is not surpris-
ing, since progression of this lesion type is associated with the acquisi-
tion of MSI instead of CIN and therefore different molecular eventsMolecular proﬁling of longitudinally observed small colorectal polyps:
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BRAF mutations and CIMP positivity were present, but MLH1 was not
yet affected. Because no dysplasia was present in any of the serrated
polyps studied, this is in line with previous studies showing that
MLH1 deﬁciency coincides with dysplasia in a serrated polyp [42].
For ethical reasons, longitudinal studies leaving polyps in situ for
some years can only be done in patients with small polyps, as these
are considered low risk. As most of these polyps are still small when re-
moved after follow-up, a practical consequence is that from some
polyps only limited amounts of tumour DNA can be obtained for molec-
ular analyses after standard diagnostic procedures. As a result, only a
subset (42%) of samples could undergo the entire range ofmolecular as-
says. In addition, no paired normal tissue was available, therefore mak-
ing the analysis dependent on public databases to ﬁlter out
polymorphisms. Inherent to the fact that histopathology of these small
polyps can only be determined at one point in time, being the time of re-
section of the polyps, evaluating themorphological evolution in relation
to the biological evolution of the polyps is not feasible. Despite these
limitations, the present study uniquely provides a comprehensive over-
view of DNA copy number, mutation, CIMP andMSI proﬁling status of a
relatively large series of polyps that were followed longitudinally.
In conclusion, molecular alterations associated with colorectal ade-
noma to carcinoma progression were related to growth over time, but
were absent in regressed lesions. So far, these molecular alterations
have been mostly identiﬁed by cross-sectional observations in tissue
samples from colorectal adenomas and cancers. The present longitudi-
nal study provides in vivo support in the human setting for the func-
tional role of these molecular alterations in this process.
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